Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer
Clinical trial NCT01392521 · COMPLETED
Trial details
- NCT number
- NCT01392521
- Sponsor
- Bayer
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-07-01
- Primary completion
- 2014-02-01
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.